Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Not Confirmed
Not Confirmed
27 September, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Webinar
Not Confirmed
27 September, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
23 Jan 2024
// PRESS RELEASE
https://famar-group.com/new/new-collaboration-between-famar-and-lavipharm-joining-forces-in-the-production-of-pharmaceutical-products/
Details:
Under the collaboration, FAMAR will undertake the production of two pharmaceutical products recently added to Lavipharm’s portfolio of analgesic pharmaceutical products, Lonarid N (paracetamol) and Lonalgal (caffeine Anhydrous).
Lead Product(s): Paracetamol,Caffeine
Therapeutic Area: Immunology Brand Name: Lonarid N
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Famar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2024
Lead Product(s) : Paracetamol,Caffeine
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Famar
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, FAMAR will undertake the production of two pharmaceutical products recently added to Lavipharm’s portfolio of analgesic pharmaceutical products, Lonarid N (paracetamol) and Lonalgal (caffeine Anhydrous).
Brand Name : Lonarid N
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2024
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?